Expansion of Target Treatment Sites and Therapeutic Areas and Enhancement of Product Portfolio
First written in FY2016. 25 of 44 entries say "Advanced", first in FY2017-Q1. Latest entry: FY2026.
The whole theme swung hardest in 2026: 1 of 6 companies on the "Worse" side.
3 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「In addition to the cardiovascular field, we will continue to advance measures to strengthen product rollout into non-cardiovascular fields, including peripheral vascular, cerebrovascular, abdominal vascular and gastrointestinal applications, as well as veterinary treatment and robotics (surgery).」
We continued to expand the scope of the non-cardiovascular field from peripheral, cerebrovascular, abdominal and gastrointestinal applications to include animal treatment and surgical robotics. - FY2026-H1AdvancedAnnual report
「In the non-cardiovascular field, although cerebrovascular and abdominal vascular products declined in the Chinese market, sales increased due to growth in peripheral and abdominal vascular products in the United States, Europe and Asia.」
In the non-cardiovascular field, while some products declined in China, peripheral and abdominal vascular products increased in the United States, Europe and Asia, demonstrating the contribution of the regional rollout of the product portfolio to sales growth. - FY2025AdvancedAnnual report
「In addition to the cardiovascular field, we will continue to advance measures to strengthen product rollout into non-cardiovascular fields, including peripheral vascular, cerebrovascular, abdominal vascular and gastrointestinal applications, as well as veterinary treatment and robotics (surgery).」
The Group has broadened the scope of its products and treatment areas in non-cardiovascular fields to include peripheral vascular, cerebrovascular, abdominal vascular and gastrointestinal applications, as well as veterinary treatment and surgical robotics. - FY2025-H1AdvancedAnnual report
「In Japan, net sales increased due to the sound performance of the cardiovascular field and strong performance in the non-cardiovascular field, where cerebrovascular products and peripheral vascular products (imported products) received strong market recognition.」
In Japan, cerebrovascular and peripheral vascular products received strong market recognition, resulting in higher sales in the non-cardiovascular field. Overseas, the Group explained that cerebrovascular products in China and abdominal vascular products in the United States also performed well. - FY2025-H1RestatedAnnual report
「① Strategic development of global markets and expansion into new anatomical sites and treatment areas」
The Group continues to present expansion into new anatomical sites and treatment areas as a basic policy integrated with the development of global markets. - FY2024AdvancedAnnual report
「In the non-cardiovascular field, net sales increased in all regions due to the effects of new products such as CROSSLEAD in the U.S. peripheral vascular product market and growth in abdominal products in the U.S. and Chinese markets.」
The new-product effects of CROSSLEAD and growth in abdominal products in the United States and China resulted in higher non-cardiovascular sales in all regions. - FY2024-Q3AdvancedAnnual report
「In the non-cardiovascular field, net sales increased in all regions, driven by the effects of new products such as CROSSLEAD in the U.S. peripheral vascular product market and growth in abdominal products in the U.S. and Chinese markets.」
In addition to the new-product effects of CROSSLEAD and CROSSWALK, abdominal products increased in the United States and China, resulting in higher non-cardiovascular sales in all regions. - FY2024-Q2RestatedAnnual report
「In the non-cardiovascular field, net sales increased due to growth across all fields in the Chinese market and higher sales in the U.S. market driven by the new-product effects of CROSSLEAD and CROSSWALK peripheral vascular products.」
The Group reaffirmed the expansion of its anatomical sites and treatment areas and product portfolio through the new-product effects of CROSSLEAD and CROSSWALK and growth in non-cardiovascular fields in China. - FY2024-Q1AdvancedAnnual report
「In the non-cardiovascular field, sales increased due to higher sales of peripheral vascular products in the U.S. market, driven by the new-product effects of CROSSLEAD and CROSSWALK, strong performance by abdominal vascular products in the Chinese market, and steady growth in OEM transactions, including an increase in new transactions, mainly in the United States.」
In addition to CROSSLEAD, the new-product effect of CROSSWALK was identified as a driver of increased peripheral vascular product sales in the United States, while Chinese abdominal vascular products and primarily U.S.-based OEM transactions also increased. - FY2023AdvancedAnnual report
「As a measure toward achieving this, during the consolidated fiscal year, we began selling the new “CROSSLEAD” peripheral vascular guidewire in the U.S. market.」
The Group began selling the new CROSSLEAD peripheral vascular guidewire in the U.S. market, giving concrete form to product expansion in non-cardiovascular fields. - FY2023-Q3RestatedAnnual report
「As part of the construction of our business portfolio, we will continue to pursue “the strategic development of global markets and expansion into new anatomical sites and treatment areas,” thereby completing our existing basic strategy and strengthening the earnings base of our existing businesses.」
The Group continues to expand into new anatomical sites and treatment areas as part of constructing a business portfolio integrated with global market development. - FY2023-Q2RestatedAnnual report
「As part of the construction of our business portfolio, we will continue to pursue “the strategic development of global markets and expansion into new anatomical sites and treatment areas,” thereby completing our existing basic strategy and strengthening the earnings base of our existing businesses.」
The Group continues to expand into new anatomical sites and treatment areas as part of constructing a business portfolio integrated with global market development. - FY2023-Q1AdvancedAnnual report
「As measures toward achieving this, during the three months ended the first quarter, we entered into ① a basic agreement for the exclusive distribution in Japan of Penumbra Inc.’s (U.S.) thrombus aspiration devices for peripheral vessels, ② an exclusive distribution agreement in China for DK MEDTECH (Suzhou) Co., Ltd.’s “DK Score coronary scoring balloon dilatation catheter,” and ③ issued the Group’s first “Integrated Report 2022.”」
The Group entered into exclusive distribution agreements for the rollout in Japan of thrombus aspiration devices for peripheral vessels and in China of coronary scoring balloons, advancing specific expansion of its products, treatment areas and sales regions. - FY2022-Q2RestatedAnnual report
「As part of the construction of our business portfolio, we will continue to pursue “the strategic development of global markets and expansion into new anatomical sites and treatment areas,” thereby completing our existing basic strategy and strengthening the earnings base of our existing businesses.」
The Group continues to expand into new anatomical sites and treatment areas as part of constructing a business portfolio integrated with the strategic development of global markets. - FY2022-Q1AdvancedAnnual report
「② Entered into a sales partnership agreement for KANEKA CORPORATION’s new cerebral aneurysm embolization coil in the U.S. market」
The Group entered into a partnership agreement to sell KANEKA CORPORATION’s new cerebral aneurysm embolization coil in the U.S. market, giving concrete form to expansion into cerebrovascular products and treatment areas. - FY2021AdvancedAnnual report
「In addition, in July 2021, we acquired a distributor in Italy and shifted to direct sales.」
The Group shifted to direct sales by acquiring a distributor in Italy, giving concrete form to the expansion of its sales regions and treatment areas. - FY2021-Q3AdvancedAnnual report
「④ Similarly, it was decided to begin direct sales in Japan from late July 2021 of certain gastrointestinal guidewires, and ⑥ it was decided to acquire 株式会社A-Traction in July 2021 to promote robotics.」
The Group is advancing specific measures to expand treatment areas, including gastrointestinal applications and robotics, through direct domestic sales of gastrointestinal guidewires and the decision to acquire a laparoscopic surgery support robotics company. - FY2021-Q2RestatedAnnual report
「By pursuing “the strategic development of global markets and expansion into new anatomical sites and treatment areas,” we aim to complete our existing basic strategy and strengthen the earnings base of our existing businesses.」
The Group continues to expand into new anatomical sites and treatment areas as part of developing global markets and constructing its business portfolio. - FY2021-Q1RestatedAnnual report
「By pursuing “the strategic development of global markets and expansion into new anatomical sites and treatment areas,” we aim to complete our existing basic strategy and strengthen the earnings base of our existing businesses.」
The Group continues to expand into new anatomical sites and treatment areas as part of constructing a business portfolio integrated with the strategic development of global markets. - FY2020RestatedAnnual report
「Based on the five-year medium-term management plan “ASAHI Road to 1000: Aiming to become a strong global niche No. 1 through Only One technology,” the Group is pursuing “strategic development of global markets and expansion of affected areas and treatment fields” as it builds a business portfolio aimed at achieving ¥100 billion in consolidated net sales. Through this initiative, it is consolidating its basic strategies to date and strengthening the earnings base of its existing businesses.」
The Group continues to expand into new anatomical sites and treatment areas as part of constructing a business portfolio integrated with the strategic development of global markets. - FY2020-Q3RestatedAnnual report
「As part of building a business portfolio aimed at achieving ¥100 billion in consolidated net sales, the Company will pursue “strategic development of global markets and expansion of affected areas and treatment fields,” thereby consolidating its basic strategies to date and strengthening the earnings base of its existing businesses.」
The Group continues to expand into new anatomical sites and treatment areas as part of constructing a business portfolio integrated with the strategic development of global markets. - FY2020-Q2AdvancedAnnual report
「As a measure toward achieving this, during the six months ended the second quarter, we began selling the new nickel-titanium hybrid PTCA guidewire “MINAMO” and the balloon-tipped guiding catheter for cerebrovascular applications “Branchor.”」
The Group began selling MINAMO and Branchor, specifically expanding its products and treatment areas in the cardiovascular and cerebrovascular fields. - FY2020-Q1AdvancedAnnual report
「As a measure toward achieving this, during the three months ended the first quarter, we began limited sales of the new nickel-titanium hybrid PTCA guidewire “MINAMO” and the balloon-tipped guiding catheter for cerebral applications “Branchor.”」
The Group began limited sales of MINAMO and Branchor, specifically expanding its product portfolio of PTCA guidewires and cerebrovascular catheters. - FY2019RestatedAnnual report
「In addition, we will continue to advance the rollout of products into non-cardiovascular fields such as peripheral, abdominal and cerebrovascular applications, building on our cardiovascular expertise.」
The Group continues to roll out products into non-cardiovascular fields such as peripheral, abdominal and cerebrovascular applications by applying its cardiovascular expertise across fields and expanding overseas. - FY2019-Q3AdvancedAnnual report
「As measures toward achieving this, during the nine months ended the third quarter, we began direct sales of our core PTCA guidewires in the U.S. market; acquired shares in U.S.-based RetroVascular, Inc. (Note), which has plasma energy technology, making it a sub-subsidiary; acquired all shares of フィカス株式会社, a company certified for Type A continuous employment support, making it a non-consolidated subsidiary after the acquisition; completed construction of the Global Headquarters and R&D Center and relocated the head office to enhance research and development functions; entered into an exclusive distribution agreement for cerebrovascular products in the U.S. market; entered into a basic agreement concerning endoscopic devices for biliopancreatic procedures; and established a branch in France and decided to shift to direct sales, thereby further reinforcing the Group’s strengths.」
The Group implemented specific measures to expand its products, treatment areas and sales regions, including an exclusive distribution agreement for cerebrovascular products in the United States, a basic agreement concerning endoscopic devices for biliopancreatic procedures, and the establishment of a branch in France and decision to shift to direct sales. - FY2019-Q2RestatedAnnual report
「As part of constructing a business portfolio to achieve consolidated net sales of ¥100 billion, the Group will continue to pursue “the strategic development of global markets and expansion into new anatomical sites and treatment areas.”」
The Group has reaffirmed its policy of advancing the development of global markets and expansion into new anatomical sites and treatment areas in tandem, while constructing its business portfolio. - FY2019-Q1RestatedAnnual report
「By continuing to pursue “the strategic development of global markets and expansion into new anatomical sites and treatment areas,” we aim to complete our existing basic strategy and strengthen the earnings base of our existing businesses.」
The Group continues to pursue expansion into new anatomical sites and treatment areas in tandem with the strategic development of global markets and construction of its business portfolio. - FY2018ReframedAnnual report
「By continuing to pursue “strategic development of global markets and expansion of affected areas and treatment fields,” the Company will consolidate its basic strategies to date and strengthen the earnings base of its existing businesses.」
Expansion into new anatomical sites and treatment areas has been incorporated into the first basic policy of the new medium-term management plan and reorganized as the construction of a business portfolio integrated with the strategic development of global markets. - FY2018-Q3AdvancedAnnual report
「As measures toward achieving this, during the nine months ended the third quarter, we began operating the newly established medical factory at TOYOFLEX CEBU CORPORATION (the Cebu manufacturing plant in the Philippines), acquired all shares of 日本ケミカルコート株式会社, which has resin coating technology (making it a non-consolidated subsidiary after the acquisition), began selling the “Silverway” guidewire for diagnostic procedures, and resolved to begin direct sales from July 2018 of our core PTCA guidewires in the U.S. market, further reinforcing the Group’s strengths.」
The product portfolio was specifically expanded through the launch of sales of the “Silverway” guidewire for diagnostic procedures. - FY2018-Q2RestatedAnnual report
「Under the ongoing medium-term management plan “Global Expansion 2018,” the Group has adopted the following management strategies and is working to enhance corporate value: “strengthening the earnings base on a global scale,” “expansion into new anatomical sites and treatment areas and enhancement of the product portfolio,” “creating innovation by strengthening materials research and production technologies,” and “optimizing group management.”」
The Group is reiterating the expansion into new anatomical sites and treatment areas and enhancement of the product portfolio as a basic policy under its medium-term management plan. - FY2018-Q1RestatedAnnual report
「Under the ongoing medium-term management plan “Global Expansion 2018,” the Group has adopted the following management strategies and is working to enhance corporate value: “strengthening the earnings base on a global scale,” “expansion into new anatomical sites and treatment areas and enhancement of the product portfolio,” “creating innovation by strengthening materials research and production technologies,” and “optimizing group management.”」
The Group is reiterating the expansion into new anatomical sites and treatment areas and enhancement of the product portfolio as a basic policy under its medium-term management plan. - FY2017RestatedAnnual report
「(b) Expansion into new anatomical sites and treatment areas and enhancement of the product portfolio」
The Group continues to pursue the expansion of cardiovascular products, reinforcement of its catheter business, and expansion into non-cardiovascular fields such as peripheral, abdominal and cerebrovascular applications. - FY2017-Q3AdvancedAnnual report
「As measures toward achieving this, during the nine months ended the third quarter, we began selling the “NC-KAMUI” high-pressure PTCA balloon catheter in the cardiovascular field and the “M-ThroughTM” endoscopic guidewire for the bile duct, pancreatic duct and gastrointestinal fields, a new business area, in Japan. In overseas markets, we advanced the rollout of products already sold and highly regarded in Japan. In Europe, we began selling the “Caravel” and “Corsair Pro” crossing catheters and the “Hyperion” PTCA guiding catheter in the cardiovascular field, and in the United States, we began selling products including the “Corsair Pro” crossing catheter in the cardiovascular field.」
The Group began selling NC-KAMUI and M-Through in Japan, Caravel, Corsair Pro and Hyperion in Europe, and Corsair Pro in the United States, advancing the rollout of products and treatment areas. - FY2017-Q2RestatedAnnual report
「As a measure toward achieving this, during the six months ended the second quarter, we began selling the “M-ThroughTM” endoscopic guidewire for the bile duct, pancreatic duct and gastrointestinal fields in Japan, which are new areas for our business. In overseas markets, we began selling the “Caravel” crossing catheter and “Hyperion” PTCA guiding catheter in Europe, both of which are already sold and highly regarded in Japan, and changed our sales strategy in China to a model involving sales through multiple distributors for cardiovascular products.」
The Group is reiterating initiatives to expand into the bile duct, pancreatic duct and gastrointestinal fields in Japan, sell catheters in Europe, and pursue a multiple-distributor model in China. - FY2017-Q1AdvancedAnnual report
「As a measure toward achieving this, during the three months ended the first quarter, we began selling the “M-ThroughTM” endoscopic guidewire for the bile duct, pancreatic duct and gastrointestinal fields in Japan, which are new areas for our business. In overseas markets, we also began limited sales in Europe of the “Caravel” crossing catheter and “Hyperion” PTCA guiding catheter in the cardiovascular field, both of which are already sold and highly regarded in Japan, as well as peripheral guidewires for the non-cardiovascular peripheral vascular field.」
The Group began selling endoscopic guidewires in new areas such as the gastrointestinal field and limited sales of catheters and peripheral vascular products in Europe. These initiatives demonstrate specific expansion into new anatomical sites and treatment areas and of the product portfolio. - FY2016First statedAnnual report
「Expansion of Target Treatment Sites and Therapeutic Areas and Enhancement of Product Portfolio」
The Group plans to expand its core cardiovascular product lineup, while advancing its business into catheters and peripheral, abdominal and cerebrovascular fields.